{"disease":{"id":"thyroid-papillary-carcinoma","name":"thyroid papillary carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06583057","title":"Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05191927","title":"A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07357571","title":"Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06971965","title":"Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":578,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT06261190","title":"Active Surveillance for Low-risk Papillary Thyroid Carcinoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":499,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04624477","title":"Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06439745","title":"More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06730893","title":"Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":310,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04411290","title":"Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Umraniye Education and Research Hospital","has_results":false},{"nct_id":"NCT01208051","title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03411187","title":"Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Bo Wang,MD","has_results":false},{"nct_id":"NCT03454477","title":"Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03753919","title":"Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT00381641","title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02393690","title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT02973997","title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT07536412","title":"Decision Aid Efficacy in Low Risk Thyroid Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT02152995","title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06959641","title":"XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07376837","title":"Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04759911","title":"Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01811212","title":"Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05575440","title":"Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04985604","title":"Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Day One Biopharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06440850","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04544111","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00470496","title":"Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05410821","title":"Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT03914300","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03630120","title":"Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04129411","title":"Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03506048","title":"Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05003856","title":"Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule","phase":"NA","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}